Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results

Acceleron Pharma (XLRN) PT Raised to $62 at H.C. Wainwright

November 7, 2017 2:02 PM EST

H.C. Wainwright analyst Edward White raised his price target on Acceleron Pharma (NASDAQ: XLRN) to $62.00 (from $57.00) while maintaining a Buy rating.

White notes Luspatercept and Sotatercept updates expected at ASH.

... More

Acceleron Pharma (XLRN) Misses Q3 EPS by 1c

November 7, 2017 7:07 AM EST

Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.65), $0.01 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.82 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

... More